Illumina, Inc. — Q1 2016 Form 10-Q Summary
Business context and reporting period
Illumina develops DNA sequencing and array-based technologies for research, clinical, oncology, reproductive health, agriculture, and other applied markets. The filing covers the 13-week quarter ended April 3, 2016, compared with the 13-week quarter ended March 29, 2015. Results are unaudited and presented under U.S. GAAP.
Key financial metrics
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Total revenue | $571.8 million | $538.6 million | +6.2% |
| Product revenue | $482.8 million | $459.1 million | +5.1% |
| Service and other revenue | $89.0 million | $79.4 million | +12.0% |
| Gross profit | $397.1 million | $375.0 million | +5.9% |
| Gross margin | 69.4% | 69.6% | Down 0.2 percentage points |
| Income from operations | $121.4 million | $176.1 million | Down $54.7 million |
| Net income attributable to Illumina stockholders | $89.6 million | $136.7 million | Down 34.4% |
| Diluted EPS | $0.60 | $0.92 | Down $0.32 |
| Cash flow from operations | $39.7 million | $66.8 million | Down $27.0 million |
| Capital expenditures | $53.4 million | $36.6 million | +46.2% |
Consumables revenue increased 17% to $360.8 million, driven by growth in the sequencing instrument installed base. Instrument revenue declined 20% to $117.6 million, primarily because of lower HiSeq X shipments. Service and other revenue grew 12% to $89.0 million, supported by extended maintenance contracts.
Operating expenses increased 39% to $275.6 million. Research and development rose 35% to $124.0 million, and selling, general and administrative expense rose 28% to $149.2 million. Q1 2016 included $2.0 million of patent-litigation charges and approximately $5.4 million of GRAIL and Helix costs. Q1 2015 benefited from a $9.9 million acquisition-related gain and a $12.6 million cost-method investment gain, neither of which recurred.
Financial position, debt, and liquidity
| Balance-sheet item | April 3, 2016 | January 3, 2016 |
|---|---|---|
| Cash and cash equivalents | $754.9 million | $768.8 million |
| Short-term investments | $588.2 million | $617.5 million |
| Total cash, cash equivalents, and short-term investments | Approximately $1.3 billion | Not clearly stated |
| Total assets | $3.79 billion | $3.69 billion |
| Long-term debt | $1.02 billion | $1.02 billion |
| Total stockholders’ equity | $2.07 billion | $1.85 billion |
The company stated that existing cash, cash equivalents, short-term investments, and expected operating cash flow should fund capital and operating needs for at least the next 12 months. Approximately $467 million of cash was held by foreign subsidiaries, and $136.3 million of cash held by GRAIL and Helix was restricted to those entities’ obligations.
Outstanding convertible notes consisted of $632.5 million of 0% notes due 2019 and $517.5 million of 0.5% notes due 2021. All 2016 Notes were converted by March 11, 2016; during the quarter, $75.5 million of principal was paid in cash and $63.8 million of conversion value was paid in shares.
Material changes versus the prior comparable period
- Revenue growth was driven primarily by sequencing consumables and services, while instrument revenue declined.
- Gross margin contracted modestly because of unfavorable instrument mix and lower service margin, partly offset by a greater mix of sequencing consumables.
- Profitability declined substantially as operating expenses rose and prior-year acquisition and investment gains did not recur.
- Operating cash flow fell to $39.7 million from $66.8 million, while capital expenditures increased to $53.4 million.
- Investing cash use improved to $43.6 million from $154.1 million, largely because purchases and maturities of marketable securities were lower in net terms.
- GRAIL became a consolidated variable interest entity in January 2016. Illumina held approximately 52% of GRAIL on a fully diluted basis and consolidated $80.0 million of third-party financing as noncontrolling interest.
- The company completed two acquisitions in January 2016, paying $17.9 million in net cash and recording $23.4 million of additional goodwill.
Guidance, outlook, commentary, and risks
The filing does not provide specific quarterly or full-year revenue, earnings, or margin guidance. Management expects sequencing consumables demand to continue benefiting from growth in the installed base and sample volumes. Management expects array demand to face migration toward sequencing and lower-complexity, lower-priced products, partially offset by demand in reproductive health, agriculture, and applied markets.
Management expects research and development and selling, general and administrative expenses to continue growing. Future gross margins are expected to depend on pricing, sales and product mix, new products, royalties, manufacturing costs, and product-support obligations.
- The company accrued $21.0 million for legal contingencies as of April 3, 2016, primarily relating to patent litigation. Ultimate losses may exceed recorded accruals, and the filing states that outcomes cannot currently be predicted.
- On April 14, 2016, the company committed to invest $100.0 million in a new venture capital fund; the commitment is callable over 10 years, with up to $40.0 million drawable in the first year.
- Helix noncontrolling investors may have future cash redemption rights; the related fair value was $32.6 million at April 3, 2016. Certain GRAIL awards also contain future redemption provisions.
- Key risks include product development and commercialization, manufacturing execution, acquisition integration, competition and market conditions, taxation, foreign exchange, and litigation.
- No material changes to previously disclosed risk factors or market risks were reported, and the company reported no off-balance-sheet arrangements.
Investor verification checklist
- Verify whether consumables growth and the sequencing installed base offset continuing weakness in instrument shipments.
- Assess whether elevated R&D and SG&A spending produces corresponding product launches and revenue growth.
- Review the sustainability of the 69.4% gross margin and the effect of product and service mix.
- Monitor operating cash conversion, inventory and receivables growth, and capital-expenditure requirements.
- Evaluate GRAIL and Helix funding needs, consolidation effects, restricted cash, and potential redemption obligations.
- Review the $21.0 million legal contingency accrual and developments in patent litigation.
- Confirm the timing and financial impact of the $100.0 million venture capital commitment and future convertible-note obligations.